ImpediMed Ltd
ImpediMed Limited is an Australia-based medical technology company.
The business
ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. Its SOZO Applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp Analysis, and HF-Dex Analysis for Heart Failure. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.
Small Caps Research
No research on ImpediMed Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise IPD based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
ImpediMed’s BIS technology gains recognition as NCCN includes in oncology guidelines for lymphoedema assessment
A screening platform developed by ImpediMed (ASX: IPD) for the assessment of lymphoedema is expected to increase its profile with the announcement that bioimpedance spectroscopy (BIS) has achieved inclusion in oncology guidelines released by the National Comprehensive Cancer Network (NCCN). BIS analysis is a noninvasive, low-cost procedure which can accurately measure a patient’s total body […]
AstraZeneca sources ImpediMed’s SOZO devices for upcoming clinical trial
Medical technology company ImpediMed (ASX: IPD) unveiled a timely contract valued at over $2 million for its SOZO digital health platform, which paves the way for it to be used in a clinical trial by global biopharmaceutical giant AstraZeneca. The company said around 175 of its SOZO devices will be used in a phase II […]
ImpediMed welcomes NCCN’s updated breast cancer guidelines to provide early lymphoedema screening
The National Comprehensive Care Network (NCCN) has updated its Guidelines for Breast Cancer regarding early detection and diagnosis of lymphoedema, which ImpediMed (ASX: IPD) hopes to take advantage of with its non-invasive bioimpedance spectrometry (BIS) test and Lymphoedema Prevention Program (LPP). The update follows requests from Vanderbilt University School of Nursing, Lymphatic Education and Research […]
ImpediMed offers first glimpse into PREVENT trial results
Medical device manufacturer ImpediMed (ASX: IPD) has provided an early insight into forthcoming results from its PREVENT trial by publishing “the first of a number of manuscripts” from its ongoing trial. The latest results were published in ‘Lymphatic Research and Biology’ magazine, indicating that L-Dex is “very sensitive” in the assessment of sub-clinical lymphoedema in […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.